← PTC THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $82.7m |
$194.4m
+135.04%
|
$264.7m
+36.19%
|
$307.0m
+15.96%
|
$380.8m
+24.04%
|
$538.6m
+41.45%
|
$698.8m
+29.75%
|
$937.8m
+34.20%
|
$806.8m
-13.97%
|
$1.7b
+114.51%
|
$1.0b
-41.71%
|
|
| Cost of Revenue | $0 | $4.6m |
$12.7m
+176.82%
|
$12.1m
-4.22%
|
$567.4m
+4575.48%
|
$627.3m
+10.56%
|
$820.2m
+30.76%
|
$1.0b
+27.38%
|
$808.4m
-22.62%
|
$516.6m
-36.10%
|
$70.7m
-86.32%
|
|
| Gross Profit (Calculated) (derived) | $82.7m |
$189.8m
+129.51%
|
$252.1m
+32.79%
|
$294.8m
+16.97%
|
($186.6m)
-163.29%
|
($88.7m)
+52.48%
|
($121.4m)
-36.92%
|
($107.0m)
+11.90%
|
($1.7m)
+98.45%
|
$1.2b
+73281.31%
|
— | |
| Research and Development Expense | $117.6m | $117.5m | $172.0m | $257.5m | $477.6m | $540.7m | $651.5m | $666.6m | $534.5m | $455.2m | $433.3m | |
| General and Administrative Expense | $97.1m | $121.3m | $153.5m | $202.5m | $245.2m | $285.8m | $326.0m | $332.5m | $300.9m | $347.1m | — | |
| Amortization of Intangible Assets | — | $15.4m | $22.9m | $27.6m | $36.9m | $54.8m | $116.6m | $222.6m | $60.7m | $24.7m | — | |
| Operating Lease, Expense | — | — | $2.7m | $6.0m | $15.3m | $21.4m | $25.2m | $29.0m | $24.9m | $21.1m | — | |
| Operating Expenses | $214.8m | $258.7m | $380.4m | $548.1m | $812.5m | $913.0m | $1.1b | $1.4b | $1.1b | $863.7m | $892.0m | |
| Operating Income (Loss) | ($132.1m) |
($64.3m)
+51.32%
|
($115.7m)
-79.94%
|
($241.2m)
-108.46%
|
($431.8m)
-79.04%
|
($374.4m)
+13.28%
|
($447.4m)
-19.49%
|
($439.5m)
+1.77%
|
($302.6m)
+31.16%
|
$866.9m
+386.52%
|
$116.7m
-86.54%
|
|
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | $4.4m | — | — | — | |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | ($16.9m) | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($1.2m) | ($1.3m) | $129k | $13.7m | $85.2m | ($57.9m) | ($49.2m) | $10.1m | $6.5m | ($18.1m) | — | |
| Interest Income (Expense), Nonoperating, Net | ($8.3m) | ($12.1m) | ($12.6m) | ($12.5m) | ($56.4m) | ($86.0m) | ($90.9m) | ($129.2m) | ($167.0m) | ($152.2m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $132.1m | ($54.6m) | ($68.5m) | ($231.9m) | ($452.5m) | ($487.7m) | ($591.1m) | ($784.7m) | ($598.8m) | $1.2b | ($67.1m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($141.5m) | ($77.7m) | ($128.1m) | ($239.9m) | ($402.9m) | ($518.3m) | ($587.5m) | ($696.1m) | ($363.1m) | $696.6m | ($67.1m) | |
| Income Tax Expense (Benefit) | $569k | $1.3m | ($29k) | $11.7m | $35.2m | $5.6m | ($28.5m) | ($69.5m) | $176k | $14.0m | ($28.7m) | |
| Net Income (Loss) Attributable to Parent | ($142.1m) |
($79.0m)
+44.41%
|
($128.1m)
-62.13%
|
($251.6m)
-96.42%
|
($438.2m)
-74.17%
|
($523.9m)
-19.57%
|
($559.0m)
-6.70%
|
($626.6m)
-12.09%
|
($363.3m)
+42.02%
|
$682.6m
+287.90%
|
($38.4m)
-105.62%
|
|
| Earnings Per Share, Basic | — | — | — | ($4.27) | ($6.64) | ($7.43) | ($7.79) | ($8.37) | ($4.73) | $8.58 | ($0.67) | |
| Earnings Per Share, Diluted | ($4.17) | ($2.02) | ($2.75) | ($4.27) | ($6.64) | ($7.43) | ($7.79) | ($8.37) | ($4.73) | $7.78 | ($0.67) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 70.5m | 71.7m | 74.8m | 76.8m | 79.5m | 81.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 70.5m | 71.7m | 74.8m | 76.8m | 88.3m | 91.0m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | ($8.9m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.